Product Description
Meloxicam (Mobic trade mark, Boehringer Ingelheim) is a relatively new oral non-steroidal anti-inflammatory drug (NSAID) approved for the treatment of osteoarthritis in the US. It has also been evaluated for the treatment of rheumatoid arthritis, ankylosing spondylitis and acute 'rheumatic' pain. Meloxicam has been shown to be COX-2 preferential, particularly at its lowest therapeutic dose, and is anti-inflammatory by inhibiting prostanoid synthesis in inflammatory cells. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/12387696/)
Mechanisms of Action: COX Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral,Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | India | Indonesia | Ireland | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Pain Unspecified | Arthritis | Osteoarthritis | Arthritis, Juvenile | Arthritis, Rheumatoid | Arthritis | Osteoarthritis | Pain Unspecified | Arthritis, Juvenile | Arthritis, Rheumatoid | Arthritis | Osteoarthritis
Known Adverse Events: Diarrhea | Respiratory Tract Infections | Dyspepsia | Influenza, Human | Anemia
Company: Boehringer Ingelheim
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 4
Highest Development Phases
Phase 3: Abdominal Pain
Phase 2: Pain, Postoperative
Phase 1: Healthy Volunteers|Pain Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| MLI-RD85-P2-2023 | P2 |
Not yet recruiting |
Pain, Postoperative |
2023-12-01 |
32% |
| CTR20231766 | P1 |
Completed |
Pain Unspecified|Healthy Volunteers |
2023-08-25 |
|
| SYH9015-002 | P3 |
Completed |
Abdominal Pain |
2023-07-11 |
95% |
| CTR20230228 | P3 |
Not yet recruiting |
Abdominal Pain |
None |